MCID: HMG002
MIFTS: 51

Hemoglobinuria

Categories: Blood diseases, Immune diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to paroxysmal nocturnal hemoglobinuria and aplastic anemia, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and kidney, and related phenotype is hematopoietic system.

Wikipedia : 76 In medicine, hemoglobinuria or haemoglobinuria is a condition in which the oxygen transport protein... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 paroxysmal nocturnal hemoglobinuria 32.9 C5 CD14 CD55 CD58 CD59 FCGR3B
2 aplastic anemia 32.1 CD55 CD59 EPO PIGA
3 myelodysplastic syndrome 29.9 CD55 CD59 CR1 EPO PIGA
4 hemolytic anemia 29.9 C3 CD55 CD59 EPO HP PIGA
5 anemia, autoimmune hemolytic 29.9 C3 CD55 CD59 HP
6 systemic lupus erythematosus 29.3 C3 C5 CD59 CR1 FCGR3B
7 malaria 29.1 CD55 CR1 EPO HP PLAUR
8 paroxysmal cold hemoglobinuria 12.6
9 paroxysmal nocturnal hemoglobinuria 1 12.5
10 paroxysmal nocturnal hemoglobinuria 2 12.4
11 blackwater fever 11.4
12 blood group, globoside system 11.0
13 warm antibody hemolytic anemia 11.0
14 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.6
15 thrombosis 10.6
16 budd-chiari syndrome 10.4
17 leukemia 10.3
18 hemoglobinemia 10.3
19 thrombophilia due to thrombin defect 10.3
20 multiple congenital anomalies-hypotonia-seizures syndrome 10.2 PIGA PIGT
21 thrombocytopenia 10.2
22 hematopoietic stem cell transplantation 10.2
23 lymphocytic leukemia 10.2
24 multiple congenital anomalies-hypotonia-seizures syndrome 2 10.1 CD55 CD59 PIGA
25 acquired angioedema 10.1 C3 HP
26 pneumococcal meningitis 10.1 C3 C5
27 myoglobinuria 10.1
28 dense deposit disease 10.1 C3 C5
29 multiple congenital anomalies-hypotonia-seizures syndrome 3 10.1 CD55 CD59 PIGT
30 lymphoma 10.1
31 purpura 10.1
32 retinitis pigmentosa and erythrocytic microcytosis 10.1 EPO PIGA
33 neutropenia 10.1
34 heparin-induced thrombocytopenia 10.1
35 complement factor i deficiency 10.0 C3 CR1
36 complement deficiency 10.0 C3 C5
37 myelofibrosis 10.0
38 hemosiderosis 10.0
39 pancytopenia 10.0
40 leukemia, chronic lymphocytic 2 9.9
41 leukemia, chronic lymphocytic 9.9
42 myeloma, multiple 9.9
43 acute leukemia 9.9
44 hepatitis 9.9
45 disseminated intravascular coagulation 9.9
46 hemolytic-uremic syndrome 9.9
47 iron metabolism disease 9.9
48 myeloid leukemia 9.9
49 fasciitis 9.9
50 inherited bone marrow failure syndromes 9.9

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

MGI Mouse Phenotypes related to Hemoglobinuria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.32 C3 CD14 CD55 CD59 EPO FCGR3B

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 2 94-09-7, 1994-09-7 2337
2 tannic acid Approved Phase 4,Phase 2
3
Lenograstim Approved, Investigational Phase 4,Phase 2,Not Applicable 135968-09-1
4
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Pharmaceutical Solutions Phase 4,Phase 2,Not Applicable
8
Iodine Approved, Investigational Phase 3 7553-56-2 807
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
10
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
11
Methotrexate Approved Phase 3,Phase 2 59-05-2, 1959-05-2 126941
12
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
13
Fludarabine Approved Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
14
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
15
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
16 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antilymphocyte Serum Phase 3,Phase 2,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antibodies Phase 3,Phase 2,Not Applicable
22 Immunoglobulins Phase 3,Phase 2,Not Applicable
23 Muromonab-CD3 Phase 3,Phase 2
24 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
25 Thymoglobulin Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
26 Antimetabolites Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27 diuretics Phase 3
28 Natriuretic Agents Phase 3
29 Complement System Proteins Phase 3,Phase 2,Phase 1
30 Complement Inactivating Agents Phase 3,Phase 1,Phase 2
31 Protein Kinase Inhibitors Phase 3
32 Mitogens Phase 3
33
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
34
alemtuzumab Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 216503-57-0
35
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 1, Phase 2 62-90-8 229455
36
Nandrolone decanoate Approved, Illicit Phase 1, Phase 2 360-70-3 9677
37
Melphalan Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
38
Basiliximab Approved, Investigational Phase 2 152923-56-3, 179045-86-4
39
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 24356-66-9 32326 21704
40
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
41
Busulfan Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
42
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
43
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
44
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
45
Mechlorethamine Approved, Investigational Phase 2,Not Applicable 51-75-2 4033
46
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
47
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
48
Mesna Approved, Investigational Phase 2 3375-50-6 598
49
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
50
Hydroxyurea Approved Phase 1, Phase 2,Phase 2 127-07-1 3657

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
2 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
3 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00867932 Phase 4 Eculizumab
4 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
5 Transfusion Requirements in Critically Ill Oncologic Patient Unknown status NCT01648946 Phase 3
6 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00098280 Phase 3 Eculizumab
7 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00130000 Phase 3 Eculizumab
8 Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT00112983 Phase 3
9 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00122317 Phase 3 eculizumab
10 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT00122330 Phase 3 eculizumab
11 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed NCT00122304 Phase 3 eculizumab
12 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
13 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
14 Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
15 Transfusion-requirements in Septic Shock Trial Completed NCT01485315 Phase 3
16 Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 Recruiting NCT03588026 Phase 3 rVA576
17 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03406507 Phase 3
18 Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH Recruiting NCT03500549 Phase 3 APL-2;Soliris
19 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
20 ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
21 ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Active, not recruiting NCT01774721 Phase 3 Dacomitinib (PF-00299804);Gefitinib
22 Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Enrolling by invitation NCT03531255 Phase 3 APL-2
23 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
24 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
25 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
26 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
27 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure Unknown status NCT00895739 Phase 2 cyclosporine
28 Nandrolone Decanoate in the Treatment of Telomeropathies Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
29 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Completed NCT02591862 Phase 2 Coversin
30 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT03053102 Phase 2 ACH-0144471
31 Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01192399 Phase 2
32 E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01194804 Phase 2 Eculizumab
33 Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Completed NCT00004464 Phase 2 cyclophosphamide;filgrastim
34 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab Completed NCT03030183 Phase 2 RA101495
35 Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Completed NCT03078582 Phase 2 RA101495
36 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
37 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
38 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
39 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
40 Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Completed NCT00731328 Phase 2
41 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
42 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
43 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
44 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
45 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
46 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
47 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases Completed NCT02277639 Phase 2
48 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
49 Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03439839 Phase 2 LNP023
50 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab Recruiting NCT03472885 Phase 2 ACH-0144471;Eculizumab

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

41
Bone, Bone Marrow, Kidney, T Cells, Testes, Neutrophil, Monocytes

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 1197)
# Title Authors Year
1
Comparison of High Sensitivity and Conventional Flow Cytometry for Diagnosing Overt Paroxysmal Nocturnal Hemoglobinuria and Detecting Minor Paroxysmal Nocturnal Hemoglobinuria Clones. ( 30430777 )
2019
2
Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children. ( 29722478 )
2018
3
Microangiopathy and acute kidney injury in paroxysmal cold hemoglobinuria: A challenge for management. ( 29341234 )
2018
4
Maintenance of renal function in a patient with a history of acute paroxysmal nocturnal hemoglobinuria-associated kidney injury. ( 29527312 )
2018
5
Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. ( 29912864 )
2018
6
Paroxysmal nocturnal hemoglobinuria: Kidney biopsy and magnetic resonance imaging. ( 29629284 )
2018
7
High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections. ( 29599976 )
2018
8
Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. ( 29467851 )
2018
9
The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. ( 29246924 )
2018
10
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. ( 29314145 )
2018
11
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing. ( 29236353 )
2018
12
Eculizumab treatment for ischemic enteritis accompanied with paroxysmal nocturnal hemoglobinuria: a case report and literature review. ( 29532162 )
2018
13
Utility of CD157 as a Common Leukocytes Marker for Paroxysmal Nocturnal Hemoglobinuria Screening in a Single Tube Five Color Combination. ( 29622874 )
2018
14
Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. ( 29102415 )
2018
15
Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. ( 29021487 )
2018
16
Introduction to ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria and related disorders. ( 29389086 )
2018
17
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. ( 29236352 )
2018
18
Risk factors for hemoglobinuria after ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous hemangiomas. ( 29876018 )
2018
19
Concurrent treatment of aplastic anemia/Paroxysmal Nocturnal Hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. ( 29545341 )
2018
20
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3 - data analysis, reporting and case studies. ( 29236350 )
2018
21
Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. ( 29749402 )
2018
22
Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. ( 29721255 )
2018
23
Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. ( 29383624 )
2018
24
Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients. ( 29323198 )
2018
25
Paroxysmal cold hemoglobinuria with acute renal failure. ( 29853460 )
2018
26
Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. ( 29486674 )
2018
27
Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. ( 29532535 )
2018
28
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. ( 30370949 )
2018
29
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. ( 29131151 )
2018
30
Ecthyma Gangrenosum in Paroxysmal Nocturnal Hemoglobinuria. ( 30300881 )
2018
31
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 4 - assay validation and quality assurance. ( 29251828 )
2018
32
CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. ( 29551496 )
2018
33
Correction to: Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. ( 29980910 )
2018
34
Bone Marrow as a Source of Cells for Paroxysmal Nocturnal Hemoglobinuria Detection. ( 29982419 )
2018
35
Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. ( 30032748 )
2018
36
Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. ( 30032754 )
2018
37
Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. ( 30039297 )
2018
38
Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria-Return to Health or Transition Into Malignancy? ( 30116241 )
2018
39
Utility of dynamic contrast-enhanced MRI to assess small bowel perfusion in paroxysmal nocturnal hemoglobinuria before and after eculizumab. ( 30126686 )
2018
40
Eculizumab application during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: A case report with review of the literature. ( 30147909 )
2018
41
Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. ( 30171081 )
2018
42
Paroxysmal nocturnal hemoglobinuria. ( 30193519 )
2018
43
The Role of Whole-Body Magnetic Resonance Imaging (WB-MRI) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). ( 30194314 )
2018
44
Therapeutic challenges in pregnant women with paroxysmal nocturnal hemoglobinuria: A case report. ( 30200112 )
2018
45
Preoperative administration of eculizumab to prevent surgery-triggered hemolysis during cesarean section with paroxysmal nocturnal hemoglobinuria. ( 30214768 )
2018
46
How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. ( 30242915 )
2018
47
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. ( 30287620 )
2018
48
Iron Deficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Cross-Sectional Survey from a Single Institution in China. ( 30306969 )
2018
49
Hemosiderin tubulopathy-induced acute kidney injury - A rare initial manifestation of paroxysmal nocturnal hemoglobinuria. ( 30381527 )
2018
50
Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications. ( 30464689 )
2018

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 C3 C5 CD14 CD55 CD58 CD59
2
Show member pathways
12 C3 CR1 FCGR3B
3 11.96 C3 CD14 CR1 FCGR3B
4 11.89 C3 CD14 FCGR3B
5
Show member pathways
11.88 C3 C5 CD55 CD59 CR1
6
Show member pathways
11.78 C3 C5 CD55 CD59 CR1
7 11.76 CD14 CD59 EPO
8
Show member pathways
11.66 FCGR3B PIGA PIGT PLAUR
9 11.62 C3 CR1 FCGR3B
10
Show member pathways
11.58 C3 C5 CD55 CD59 CR1
11 11.55 C3 C5 CD14
12 11.38 C3 C5 FCGR3B
13 11.35 C3 CD14 CR1
14 11.34 CD14 CD55 CD59 CR1 EPO
15 11.24 C3 C5 CD55 CD59 CR1 PLAUR
16
Show member pathways
11.17 PIGA PIGT

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 C3 C5 CD14 CD55 CD59 EPO
2 extracellular exosome GO:0070062 9.96 C3 C5 CD14 CD55 CD58 CD59
3 extracellular space GO:0005615 9.95 C3 C5 CD14 CD59 EPO HP
4 cell surface GO:0009986 9.7 CD14 CD55 CD58 CD59 CR1 EPO
5 ficolin-1-rich granule membrane GO:0101003 9.54 CD55 CD58 CR1
6 anchored component of external side of plasma membrane GO:0031362 9.43 CD14 CD59
7 secretory granule membrane GO:0030667 9.35 CD14 CD55 CD58 CR1 FCGR3B
8 anchored component of membrane GO:0031225 9.1 CD14 CD55 CD59 FCGR3B PLAUR SEMA7A

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 C3 C5 CD14 SEMA7A
2 immune system process GO:0002376 9.72 C3 C5 CD14 CD55 CR1
3 positive regulation of protein phosphorylation GO:0001934 9.69 C3 PLAUR SEMA7A
4 innate immune response GO:0045087 9.65 C3 C5 CD14 CD55 CR1
5 acute-phase response GO:0006953 9.52 EPO HP
6 GPI anchor biosynthetic process GO:0006506 9.49 PIGA PIGT
7 positive regulation of vascular endothelial growth factor production GO:0010575 9.48 C3 C5
8 response to electrical stimulus GO:0051602 9.46 CD14 EPO
9 complement activation, classical pathway GO:0006958 9.46 C3 C5 CD55 CR1
10 positive regulation of interleukin-8 secretion GO:2000484 9.4 CD14 CD58
11 complement activation, alternative pathway GO:0006957 9.37 C3 C5
12 regulation of complement activation GO:0030449 9.35 C3 C5 CD55 CD59 CR1
13 neutrophil degranulation GO:0043312 9.28 C3 CD14 CD55 CD58 CD59 CR1

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 8.96 C3 C5
2 signaling receptor binding GO:0005102 8.92 C3 C5 CD58 PLAUR

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....